[¹⁸F]FDG

Clinical Evaluation	Glucose metabolism
Type of Imaging	PET
Grade of Recommendation	B (generally recommended)
Level of Evidence	well-established clinical and NM recommendations recommendations
Effective Dose	19.0 µSv/MBq
Bibliographic Reference	Cavo, M., Terpos, E., Nanni, C. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a conse... read more Cavo, M., Terpos, E., Nanni, C. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017; https://doi.org/10.1016/S1470-2045(17)30189-4 Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019; https://doi.org/10.1016/S1470-2045(19)30309-2 Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., ... & Avet-Loiseau, H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; https://doi.org/10.1016/S1470-2045(16)30206-6 Nanni, C., Kobe, C., Baeßler, B. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. Lancet Haematol. 2023; https://doi.org/10.1016/S2352-3026(23)00030-3 read less
Guide to Nuclear Medicine	Read the corresponding chapter

Clinical Evaluation
Glucose metabolism
Type of Imaging
PET
Grade of Recommendation
B (generally recommended)
Level of Evidence
well-established clinical and NM recommendations recommendations
Effective Dose
19.0 µSv/MBq
Bibliographic Reference
Cavo, M., Terpos, E., Nanni, C. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a conse... read more Cavo, M., Terpos, E., Nanni, C. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017; https://doi.org/10.1016/S1470-2045(17)30189-4 Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019; https://doi.org/10.1016/S1470-2045(19)30309-2 Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., ... & Avet-Loiseau, H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; https://doi.org/10.1016/S1470-2045(16)30206-6 Nanni, C., Kobe, C., Baeßler, B. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. Lancet Haematol. 2023; https://doi.org/10.1016/S2352-3026(23)00030-3 read less
Guide to Nuclear Medicine
Read the corresponding chapter

[18F]FDG

[¹⁸F]FDG